Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Dsi2.0
DSIP – Forschung
Überwiegend Mechanismus / Beobachtung
9 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu DSIP sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus gemischt-qualitativen randomisierten Studien, veröffentlicht 1984–2011 mit einer typischen Studiengröße von 14 Teilnehmenden.
Basierend auf 9 Studien · 3 RCTs · 14 Teilnehmende insgesamt
Konfidenz
Mittlere Konfidenz
Nach Outcome
Sleep & insomniaDelta-Schlaf-induzierendes Peptid, untersucht für den Schlaf bei schwerer Insomnie; nur kleine, alte, uneindeutige Humandaten und unbekannte langfristige/moderne Sicherheit. · Nicht etabliert
Überwiegend Mechanismus / Beobachtung6 Studien
Anxiety & stressPostulierte stressprotektive/adaptive Wirkung (präklinisch) mit reduzierten chronischen Schmerz- und depressiven Zuständen in einer offenen Pilotstudie; Evidenz von niedriger Qualität. · Nicht etabliert
Zu wenige bewertete Studien2 Studien
Pain & analgesia
Zu wenige bewertete Studien1 Studie
Ältere Forschungsbasis
Neueste Studie von 2011
198419972011
1RCT2009
DSIP significantly increased heart rate, decreased HRV and, paradoxically, significantly reduced delta rhythm along with reducing burst suppression and increasing BIS at 25 nmol kg(-1) during isoflurane anaesthesia.
Pomfrett CJ, Dolling S, Anders NR, Glover DG, Bryan A, Pollard BJ. · Eur J Anaesthesiol (2009)
Randomized human study (24 female patients; 12 saline controls, 12 DSIP at 25/50/100 nmol/kg) testing DSIP as an adjunct to isoflurane anaesthesia
Contrary to the 'sleep-deepening' hypothesis, DSIP paradoxically reduced delta rhythm and increased the bispectral index — i.e. lightened anaesthetic depth
DSIP also increased heart rate and decreased heart-rate variability, suggesting reduced parasympathetic tone, and altered EEG hemispheric symmetry
CSF DSIP-LI was significantly correlated with polysomnography the night before the LP: with stage 3 sleep... Whether this first report of a potential relationship between CSF DSIP-LI and slow-wave sleep in man might be generalized to sleep in nonpsychiatric subjects awaits further study.
van Kammen DP, Widerlöv E, Neylan TC, Ekman R, Kelley ME, Mouton A, et al. · Sleep (1992)
Measured cerebrospinal-fluid DSIP-like immunoreactivity (DSIP-LI) and polysomnography in 15 drug-free male schizophrenic volunteers
Endogenous CSF DSIP-LI correlated with stage 3 / delta slow-wave sleep measures the night before lumbar puncture
This is a correlational study of endogenous DSIP — it did not administer exogenous DSIP
Subcutaneous injection to the rats... with 10 microg/100 g body weight of delta-sleep inducing peptide (DSIP) suppresses lipid peroxidation preventing the increasing of malonic dialdehyde level in rats tissues and plasma, possesses a powerful antioxidant effect.
Rat study of DSIP's proposed geroprotective/antioxidant mechanism across ages 2-24 months
Subcutaneous DSIP suppressed lipid peroxidation and lowered malondialdehyde in tissues and plasma
Stimulated endogenous antioxidant defences — superoxide dismutase, catalase, and ceruloplasmin activities, plus non-enzymatic antioxidants
4Tierstudie2009
Last 10% (most aged) of mice which received Deltaran lived for 16% longer than the controls... Also Deltaran slowed the spontaneous carcinogenesis parameters.
Voĭtenkov VB, Popovich IG, Zabezhinskiĭ MA, Iurova MA, Piskunova TA, Mikhaleva II. · Adv Gerontol (2009)
Female SHR mice received monthly 5-day subcutaneous courses of the DSIP preparation 'Deltaran' across their lifespan
The most-aged 10% of treated mice lived ~16% longer than controls, with higher locomotor and exploratory activity
Treated mice showed anxiolytic-type behaviour (more time in open arms of the elevated plus maze) and slowed spontaneous carcinogenesis
5RCTn=14 · very small study1987
DSIP was administered under placebo-controlled, double-blind conditions for 7 successive nights... The treatment substantially improved night sleep with the first and additionally with repeated doses... The study demonstrates the efficacy of DSIP for the treatment of impaired sleep and daytime functions as well.
Schneider-Helmert D. · Eur Neurol (1987)
Placebo-controlled, double-blind study of intermediate-term DSIP over 7 successive nights in 14 middle-aged chronic insomniacs
Reported that DSIP substantially improved night sleep (acutely and with repeated doses) and that sleep efficiency and daytime alertness/performance reached normal-control levels
Single author (Schneider-Helmert) — the same investigator behind most of the positive 1980s DSIP sleep claims
For NREM sleep time and stage 2 sleep differences between DSIP and a placebo were significant, but the same differences existed already for the baseline values. It can be concluded that sleep improvement under DSIP treatment is of little clinical significance.
Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. · Int J Clin Pharmacol Res (1987)
Double-blind, placebo-controlled crossover polysomnography trial of IV DSIP (25 nmol/kg) over four nights in insomniac patients, by an independent (Uruguayan) group
Some sleep parameters (awakenings, NREM latency, waking time) decreased under DSIP, but differences from placebo were not clearly attributable to the peptide — the same differences already existed at baseline
Slow-wave sleep (stages 3 and 4) and REM were not modified
7Übersicht1984
Two different studies showed improvement of sleep following single injections of 25 nmol/kg b.w. before sleep. Repeated administrations indicated a buildup with normalization of sleep structure after four administrations.
Schneider-Helmert D. · Eur Neurol (1984)
Summary of early human investigations of DSIP injections in insomnia
Reported improved sleep after single 25 nmol/kg subcutaneous injections before sleep, with normalization of sleep structure after repeated administration
Morning injections still improved night sleep, while two daily doses did not — pointing to a complex, non-dose-linear effect
In an open study 7 patients with severe insomnia were treated by a series of 10 injections with the delta-sleep-inducing peptide (DSIP). In all but 1 case sleep was normalized for follow-up periods of 3-7 months.
Kaeser HE. · Eur Neurol (1984)
Open (uncontrolled) study of 7 patients with severe insomnia given a series of 10 DSIP injections
Sleep was reported normalized in all but 1 patient, with follow-up of 3-7 months, and daytime mood/performance improved
Tiny, open-label, 1984 study with no placebo control — hypothesis-generating only
DSIP lowered significantly the pain levels of 6 out of 7 patients after intravenous administration on 5 consecutive days followed by 5 injections every 48-72 h. Remarkably, a simultaneous significant reduction of the concomitantly occurring depressive states was observed.